Work from a prolific father-son team of liver researchers in Germany has come under scrutiny after accusations that they falsified data in a 2009 letter to the editor that appeared in the Journal of Hepatology.
The letter, retracted in the September issue (after an online notice in June), referred to a 2008 article in the journal by Axel Gressner, his son Olav, and their colleagues at University Hospital in Aachen in which the authors reported that doses of caffeine might be an effective treatment for liver fibrosis, scarring of the organ that results from chronic ailments such as cirrhosis or hepatitis.
Epidemiologic evidence has suggested that people who drink coffee are somewhat protected from liver fibrosis—although some experts dispute the purported connection—and the German group claimed to have been among the first to find a plausible molecular mechanism for the link. Their November 2008 paper on the subject has been cited 16 times, according to Thomson Scientific’s Web of Science, a hefty number for just 22 months.
In their follow-up letter, they went a step further, stating that injecting rats with caffeine blocked the expression of a key protein associated with growth of connective tissue necessary for the formation of liver scars.
But the evidence backing the letter appears to be far weaker than the researchers initially let on. Continue reading Liver spots: Hepatology journal yanks research letter on caffeine-fibrosis link, saying authors falsified data